[1] Shi Y, Gan XN, Cai J, et al.Using bibliometrics analysis to explore the global research status and future trends of psychological problems and intervention models of cancer patients[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2021, 46(1): 120-127. [2] Cox EC, Thornlow DN, Jones MA, et al.Antibody-mediated endocy-tosis of polysialic acid enables intracellular delivery and cytotoxicity of a glycan-directed antibody-drug conjugate[J].Cancer Res, 2019, 4(15): 798-801. [3] Jeon IS, Yoo JD, Gurung S, et al.Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs[J]. Biomaterials. 2021, 270(5): 685-689. [4] National Health Commission. Notice of the National Health Commission on the issuance of the administrative measures for the clinical application of anti-tumor drugs (for trial),Guowei medical letter [2020] no. 487 [EB/OL]. (2020-12-22)[2021-03-01]. http://www.nhc.gov.cn/yzygj/s7659/202012/a7600740bed44d1db7015ca5a1be2cc0.html. [5] Cheng J, Han YX, Wang L, et al.Analysis of 54 cases of adverse reactions of novel anticancer drugs[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(3): 280-284. [6] Jia JQ, Sun YF, Qin F.Analysis of clinical use of antitumor drugs[J]. Chinese Journal of Drug Evaluation(中国药物评价), 2019, 36(5): 383-387. [7] Zhao CX, Hu ZW, Cui B.Research progress of monoclonal antibody drugs[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(6): 837-847. [8] Zhang JH, Yang JQ, Luo Y.Mining and evaluation of safety signals for monoclonal anti-tumor representative drugs after marketing[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(13):1654-1660. [9] George Mantese.Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment[J]. Current Opinion in Gastroenterology, 2019, 35(6): 23-27. [10] Fu WT, Wang KY, Song CL, et al.Investigation and analysis of off-label use of anti-tumor drugs in our hospital from 2012 to 2014 and its reasonableness evaluation[J]. China Medical Herald(中国医药导报), 2016, 13(8): 146-149. [11] Su YX, Xue P, Mao Y, et al.Clinical progress of navuliumab in the treatment of non-small cell lung cancer[J].Chinese Journal of Clinical Oncology(中国肿瘤临床), 2020, 47(6): 304-308. [12] Zhang JF, Liu C, Kai ZX, et al.Clinical significance of programmed death molecule-1 inhibitor navulliumab in the treatment of advanced renal carcinoma[J]. Journal of Modern Urology(现代泌尿外科杂志), 2020, 25(3): 280-284. [13] Zhou YW, Xia RL, Xiao HL, et al.Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer[J]. International Immunopharmacology, 2021, 9(11): 35-49. [14] Wu X, Gu Z, Chen Y, et al.Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019, 3(17): 661-674. [15] Tan JR, Hu CP.Fatal adverse reactions associated with immune checkpoint inhibitors and management strategies[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2020, 40(4): 340-344. [16] Naing A, Hajjar J, Gulley JL, et al.Strategies for improving the management of immune-related adverse events[J]. Journal For Immunotherapy of Cancer, 2020, 8(2): 78-81. |